For type 2 diabetes mellitus. ANDA 90295, held by Pharmazone. Metformin Hydrochloride.
As of Nov 16, 2026, ANDA 90295 (Metformin Hydrochloride), held by Pharmazone, was first approved by FDA on Apr 29, 2016, with 3 approved supplements and 0 published complete response letters.
Metformin Hydrochloride Extended-Release Tablets, USP is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 29, 2016 | Original application | Approved | None posted |
| Metformin Hydrochloride500MG · tablet, extended release;oral | Metformin Hydrochloride | Rx |
| Metformin Hydrochloride750MG · tablet, extended release;oral | Metformin Hydrochloride | Rx |
| Aug 11, 2026 | Supplement 10Labeling · Standard review | Approved | None posted |
| Jun 25, 2021 | Supplement 2Labeling · Standard review | Approved | None posted |
| Jun 25, 2021 | Supplement 3Labeling · Standard review | Approved | None posted |
| Apr 29, 2016 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters